Miura, Yoshitaka <br/><br/>
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.  [electronic resource] 

 -  Diabetes care  Mar 2005 
 - 757-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Letter 
<br/><br/><label>ISSN: </label>0149-5992 
<br/><br/><label>Standard No.: </label>10.2337/diacare.28.3.757  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiotensin II Type 1 Receptor Blockers--therapeutic use<br/>Angiotensin-Converting Enzyme Inhibitors--therapeutic use<br/>Benzimidazoles--therapeutic use<br/>Benzoates--therapeutic use<br/>Biphenyl Compounds<br/>Blood Pressure--drug effects<br/>Diabetes Mellitus, Type 2--complications<br/>Diabetic Angiopathies--drug therapy<br/>Female<br/>Humans<br/>Hypertension--drug therapy<br/>Male<br/>Middle Aged<br/>Telmisartan<br/>Tetrazoles--therapeutic use<br/>Valine--analogs & derivatives<br/>Valsartan